177 related articles for article (PubMed ID: 18617442)
21. [Viral inactivation of cellular blood products].
Andreu G
Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):215-6. PubMed ID: 8337130
[No Abstract] [Full Text] [Related]
22. [Apheresis donation. Current views and perspectives].
Schooneman F
Transfus Clin Biol; 2005 Jun; 12(2):208-11. PubMed ID: 15925528
[No Abstract] [Full Text] [Related]
23. [Blood products].
Montloin A
Rev Infirm; 1992 Mar; 42(6):33-41. PubMed ID: 1598492
[No Abstract] [Full Text] [Related]
24. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends.
Goodrich RP; Edrich RA; Li J; Seghatchian J
Transfus Apher Sci; 2006 Aug; 35(1):5-17. PubMed ID: 16935562
[TBL] [Abstract][Full Text] [Related]
25. 2008 Congress of the ESFH in Düsseldorf, Germany.
Moog R
Transfus Apher Sci; 2009 Aug; 41(1):23-6. PubMed ID: 19556166
[No Abstract] [Full Text] [Related]
26. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies.
Picker SM; Schneider V; Gathof BS
Transfusion; 2009 Jun; 49(6):1224-32. PubMed ID: 19220821
[TBL] [Abstract][Full Text] [Related]
27. Indications for use and cost-effectiveness of pathogen-reduced ABO-universal plasma.
Solheim BG; Chetty R; Flesland O
Curr Opin Hematol; 2008 Nov; 15(6):612-7. PubMed ID: 18832933
[TBL] [Abstract][Full Text] [Related]
28. Reflections on the dynamics of bacterial and viral contamination of blood components and the levels of efficacy for pathogen inactivation processes.
Bah A; Cardoso M; Seghatchian J; Goodrich RP
Transfus Apher Sci; 2018 Oct; 57(5):683-688. PubMed ID: 30220450
[TBL] [Abstract][Full Text] [Related]
29. A pathogen reduction clinical trial in retrospect.
Rebulla P
Blood Transfus; 2017 Jul; 15(4):329-332. PubMed ID: 28488973
[No Abstract] [Full Text] [Related]
30. Pathogen inactivation of labile blood products.
Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components
Transfus Med; 2001 Jun; 11(3):149-75. PubMed ID: 11422945
[No Abstract] [Full Text] [Related]
31. [The innocuity of stable products derived from human plasma].
Subtil E
Contracept Fertil Sex; 1993 Nov; 21(11):836. PubMed ID: 8281234
[No Abstract] [Full Text] [Related]
32. Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats.
Ciaravino V; Hanover J; Lin L; Sullivan T; Corash L
Transfusion; 2009 May; 49(5):985-94. PubMed ID: 19175545
[TBL] [Abstract][Full Text] [Related]
33. Pathogen inactivation: making decisions about new technologies - preliminary report of a consensus conference.
Klein HG; Anderson D; Bernardi MJ; Cable R; Carey W; Hoch JS; Robitaille N; Sivilotti ML; Smaill F
Vox Sang; 2007 Aug; 93(2):179-82. PubMed ID: 17683364
[No Abstract] [Full Text] [Related]
34. Updates on pathogen inactivation of plasma using Theraflex methylene blue system.
Seghatchian J; Walker WH; Reichenberg S
Transfus Apher Sci; 2008 Jun; 38(3):271-80. PubMed ID: 18487089
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of nanofiltration in removing small non-enveloped viruses from three different plasma-derived products.
Menconi MC; Maggi F; Zakrzewska K; Salotti V; Giovacchini P; Farina C; Andreoli E; Corcioli F; Bendinelli M; Azzi A
Transfus Med; 2009 Aug; 19(4):213-7. PubMed ID: 19706139
[TBL] [Abstract][Full Text] [Related]
36. Inactivation of norovirus by chlorine disinfection of water.
Shin GA; Sobsey MD
Water Res; 2008 Nov; 42(17):4562-8. PubMed ID: 18760818
[TBL] [Abstract][Full Text] [Related]
37. Susceptibility of mouse minute virus to inactivation by heat in two cell culture media types.
Schleh M; Romanowski P; Bhebe P; Zhang L; Chinniah S; Lawrence B; Bashiri H; Gaduh A; Rajurs V; Rasmussen B; Chuck A; Dehghani H
Biotechnol Prog; 2009; 25(3):854-60. PubMed ID: 19405099
[TBL] [Abstract][Full Text] [Related]
38. Commentary on the current opinions on blood components safety/efficacy.
Seghatchian J
Transfus Apher Sci; 2006 Jun; 34(3):241-2. PubMed ID: 16807111
[No Abstract] [Full Text] [Related]
39. [Virus inactivation in a single unit of plasma for transfusion].
Zhiburt EB
Med Tekh; 2008; (3):36-9. PubMed ID: 18688943
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis G virus: a suitable marker of in vivo efficacy for pathogen inactivation.
Lefrère JJ; Laperche S; Roudot-Thoraval F
Vox Sang; 2008 Jul; 95(1):76-8. PubMed ID: 18393946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
